Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells

[Background]: Primary resistance to anti-EGFR therapies affects 40% of metastatic colorectal cancer patients harbouring wild-type RAS/RAF. YAP1 activation is associated with this resistance, prompting an investigation into AURKA’s role in mediating YAP1 phosphorylation at Ser397, as observed in brea...

Descripción completa

Detalles Bibliográficos
Autores: Rio-Vilariño, Anxo, Cenigaonandia-Campillo, Aiora, García-Bautista, Ana, Mateos-Gómez, Pedro A., Schlaepfer, Marina I., Puerto-Nevado, Laura del, Aguilera, Óscar, García-García, Laura, Galeano, Carlos, Miguel, Irene de, Serrano-López, Juana, Baños, Natalia, Fernandez-Aceñero, M. Jesús, Lacal, Juan Carlos, Medico, Enzo, García-Foncillas, Jesús, Cebrián, Arancha
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/371416
Acceso en línea:http://hdl.handle.net/10261/371416
Access Level:acceso abierto
Palabra clave:Cancer stem cells
Cancer therapeutic resistance
Colorectal cancer
Descripción
Sumario:[Background]: Primary resistance to anti-EGFR therapies affects 40% of metastatic colorectal cancer patients harbouring wild-type RAS/RAF. YAP1 activation is associated with this resistance, prompting an investigation into AURKA’s role in mediating YAP1 phosphorylation at Ser397, as observed in breast cancer.

Similares en LA Referencia